Skip to content

Discovery Highlights

Protein-Protein Interactions (PPI)

In addition to exploring science by testing molecules in our disease-relevant assays, we also seek specific partnerships and collaborations. We are using PPI (protein-protein interaction) technology to produce the next class of small molecules that work like biologics but can be delivered orally for patients with inflammatory skin diseases. Specifically, we are now exploring partnerships related to PPI technologies using our two specific assays targeting the IL4-Receptor and STAT6. We invite you test your molecules for the ability to inhibit the protein-protein interactions of those targets.

Below are the two current PPI-related binding assays we offer as a first screening tool to evaluate small molecule binders.

IL-4 Receptor binding assay.

Immobilized IL-4 Receptor protein is used to assess your molecule's ability to bind to the target. This early stage assay evaluates the molecule's binding affinity to IL4R.
Read more about the IL-4R binding assay.

STAT6 binding assay

In this assay the STAT6 protein is used to assess your test molecule's ability to bind to the target. This early stage assay evaluates the molecule's binding affinity to STAT6. 

Download the Open Innovation simplified agreement to test your molecules for PPI inhibition.

Contact us to have your molecules tested for PPI effect.

 

 

Scroll to top